GLP-1 Insurance Coverage.
Who covers what in 2026. Medicare and Medicaid rules, commercial carrier matrices, HSA/FSA eligibility, prior authorization checklists, and how to win an appeal.
Key Facts
No Medicare
for weight loss. Limited coverage exists for T2D (Ozempic, Mounjaro) and cardiovascular risk reduction (Wegovy).
State-by-state
Medicaid coverage. Growing number of states cover Wegovy/Zepbound for obesity with PA requirements.
30–60 days
typical internal appeals timeline. External state review adds 30–60 days more.
Medicare & GLP-1
Medicare Part D excludes drugs "used for anorexia, weight loss, or weight gain" under the Medicare Modernization Act. GLP-1s prescribed for obesity alone are therefore not covered. Exceptions: Ozempic and Mounjaro for type 2 diabetes are broadly covered under Part D; Wegovy has a narrower Part D coverage pathway when prescribed for cardiovascular risk reduction in established CVD patients, following the SELECT trial data.
Medicaid by state
Medicaid GLP-1 coverage is determined by each state's drug formulary. Coverage has expanded rapidly since 2023; as of 2026, the majority of states cover at least one GLP-1 for obesity with prior authorization. Specific criteria (BMI thresholds, prior therapy documentation, comorbidity requirements) vary by state.
Commercial insurance
Commercial coverage for GLP-1 weight-loss medications is plan-specific. Large employer groups often carve out obesity drug coverage at plan design, so coverage depends more on your employer's benefit selection than on the insurance carrier itself. Prior authorization is nearly universal when coverage does exist.
Prior authorization checklist
Most PAs for GLP-1 obesity indication require: BMI ≥30 (or ≥27 with comorbidities), documentation of at least one prior weight-loss attempt, and a reasonable expectation that the patient will adhere to a reduced-calorie diet and increased physical activity. Some plans add: step therapy (try a cheaper agent first), behavioral health program participation, or quarterly weight-check documentation.
How to appeal a denial
The standard appeal ladder: (1) internal appeal with new clinical documentation; (2) peer-to-peer review with the plan's medical director; (3) external review through the state insurance department. Appeals win most often when they add information the initial review didn't have: documentation of failed alternative therapies, new comorbid diagnoses, or specialist letters.